Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Advanced or Metastatic Malignancies
NCT02832167Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2016
- Primary completion
- Oct 2019
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nivolumab in advanced malignant solid tumor, sponsored by Bristol Myers Squibb. Started Feb 2016; status: completed.
02
Drugs
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT02832167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02832167.